Emgality cut weekly cluster headache attacks in half or more for most patients at Week 31
71.4% of patients on Emgality achieved a ≥50% reduction from baseline vs 52.6% of patients on placebo1
ap=0.046 vs placebo
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0089. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0088. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0087. 5. Data on File. Lilly USA, LLC. DOF-GZ-US-0093.